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Background:  Over  50%  of  individuals  with  alcohol  use  disorders  (AUD)  also  use  other  substances;  brain
structural  abnormalities  observed  in  alcohol  dependent  individuals  may  not  be  entirely  related  to  alcohol
consumption.  This  MRI study  assessed  differences  in brain  regional  tissue  volumes  between  short-term
abstinent  alcohol  dependent  individuals  without  (ALC)  and  with  current  substance  use  dependence
(polysubstance  users,  PSU).
Methods:  Nineteen,  one-month-abstinent  PSU  and  40  ALC  as  well  as 27  light-drinkers  (LD)  were  studied
on  a 1.5  T MR  system.  Whole  brain  T1-weighted  images  were  segmented  automatically  into  regional  gray
matter  (GM),  white  matter  (WM),  and  cerebrospinal  fluid (CSF)  volumes.  MANOVA  assessed  group  differ-
ences of  intracranial  volume-normalized  tissue  volumes  of the  frontal,  parietal,  occipital,  and  temporal
lobes  and regional  subcortical  GM volumes.  The  volumetric  measures  were  correlated  with  neurocogni-
tive  measures  to  assess  their  functional  relevance.
Results: Despite  similar  lifetime  drinking  and  smoking  histories,  PSU  had  significantly  larger  normalized
WM  volumes  than  ALC  in  all lobes.  PSU  also  had  larger  frontal  and  parietal  WM  volumes  than  LD,  but
smaller  temporal  GM  volumes  and smaller  lenticular  and  thalamic  nuclei  than  LD.  ALC  had  smaller  frontal,
parietal,  and  temporal  GM, thalamic  GM  and cerebellar  volumes  than  LD. ALC had  more  sulcal  CSF  volumes
than  both  PSU  and  LD.
Conclusion: One-month-abstinent  ALC  and  PSU  exhibited  different  patterns  of  gross  brain  structural
abnormalities.  The  larger  lobar  WM  volumes  in  PSU  in  the  absence  of widespread  GM volume  loss con-
trast  with  widespread  GM atrophy  in  ALC.  These  structural  differences  may  demand  different  treatment
approaches  to  mitigate  specific  functionally  relevant  brain  abnormalities.
©  2014 Elsevier  Ireland  Ltd.  All  rights  reserved.
1. Introduction
Brain tissue volume losses in the frontal, temporal and select
subcortical regions of individuals with alcohol use disorders (AUD)
have consistently been reported with volumetric magnetic reso-
nance imaging (for review see Buhler and Mann, 2011), and so have
deficiencies in executive skills, learning and memory, processing
speed, visuospatial skills and working memory (Durazzo and
∗ Corresponding author at: School of Applied Sciences and Statistics, Koforidua
Polytechnic, Koforidua, Ghana. Tel.: +233 20 595 4267.
E-mail addresses: andymon2013@gmail.com, baarenaba@hotmail.com (A. Mon).
Meyerhoff, 2007; Oscar-Berman, 2000; Stavro et al., 2012). Today,
more than half of individuals with AUD who  present for treatment
also chronically abuse illicit substances (e.g., Medina et al., 2004).
Substance use disorders have adverse effects on brain biology and
function separate from those of AUD (see Barros-Loscertales et al.,
2011; Ersche et al., 2011; Fein et al., 2002; Lim et al., 2008; O’Neill
et al., 2001; Cousijn et al., 2012; Matochik et al., 2005; Yucel et al.,
2008; Berman et al., 2008; Chang et al., 2007; Thompson et al., 2004;
Tobias et al., 2010).
Comorbid alcohol and substance use disorders (i.e., polysub-
stance use disorder: PSUD) have also been associated with brain
morphological abnormalities. Liu et al. (1998) reported smaller nor-
malized gray matter (GM) and white matter (WM)  volumes of the
http://dx.doi.org/10.1016/j.drugalcdep.2014.09.010
0376-8716/© 2014 Elsevier Ireland Ltd. All rights reserved.
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prefrontal lobe in polysubstance abusers (cocaine, alcohol, heroin,
marijuana) abstinent from substance use for more than 2 weeks
compared to controls. Tanabe et al. (2009) also reported smaller
GM volumes of the bilateral medial orbitofrontal cortex in long-
term (over 2 years) abstinent individuals dependent on two  or more
substances (most often cocaine, amphetamine, and alcohol) com-
pared to controls. As in AUD, the neurobiological abnormalities in
individuals with PSUD are accompanied by cognitive deficiencies,
particularly in visual and verbal memory, attention, psychomotor
speed, visuomotor skills, problem solving and abstraction abilities
(Block et al., 2002; Medina et al., 2004).
Thus, brain morphological abnormalities appear to occur in
somewhat similar brain regions with similar neurocognitive
deficits in AUD with and without comorbid substance abuse. To
determine potential unique group differences, there is the need
to directly contrast the magnitude and spatial distribution of
structural brain abnormalities and their associated neurocogni-
tive abnormalities in AUD with and without comorbid substance
abuse. Directly contrasting structural brain abnormalities and
their neurocognitive correlates in AUD with and without sub-
stance abuse will help design more efficacious treatment strategies
tailored to individuals with PSUD or AUD. In this context, we
showed recently that one-month-abstinent treatment-seeking
PSUD individuals have prefrontal metabolite concentrations that
were uniquely different from those of alcohol dependent indi-
viduals at similar abstinence duration, reflecting neuronal and
glial dysfunction partly related to neurocognition (Abé et al.,
2013).
This quantitative volumetric magnetic resonance imaging (MRI)
study, contrasted differences in total and regional GM,  WM
and subcortical tissue volumes as well as ventricular and sulcal
cerebrospinal fluid (CSF) between abstinent alcohol dependent
individuals without current illicit substance dependence (ALC) and
those with current psychostimulant dependence (PSU). ALC and
PSU groups were abstinent from alcohol and/or psychostimulants
for about one month. The functional relevance of our MRI  measures
was assessed by correlating them with neurocognitive measures.
Since ALC recover brain tissue volume significantly but not com-
pletely within their first month of sobriety (Zipursky et al., 1989;
Durazzo et al., 2014; Gazdzinski et al., 2005a,b; Pfefferbaum et al.,
1995; Trabert et al., 1995; Van Eijk et al., 2013), while individ-
uals with PSUD show regional GM tissue volume deficits even
after many weeks and years of abstinence (Liu et al., 1998; Tanabe
et al., 2009), we tested the following hypotheses in treatment-
seeking individuals after one month of abstinence from alcohol
and other substances: (1) PSU have smaller lobar GM,  WM and
subcortical tissue volumes as well as larger CSF volumes than
light-drinking controls (LD) and ALC and (2) in PSU and in ALC,
smaller lobar GM and WM volumes correlate with worse meas-
ures of working memory, processing speed, visual-spatial learning
and memory and auditory-verbal learning and general intelli-
gence.
2. Materials and methods
2.1. Participants
Treatment-seeking PSU (n = 19) and ALC (n = 117) were recruited from the San
Francisco VA Medical Center and Kaiser Permanente. For statistical reasons, we
reduced our large ALC cohort to 40 individuals by matching them on age, educa-
tion, smoking status and drinking variables to the smaller PSU group. Both ALC and
PSU  participants completed the structured clinical interview for the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) Axis I Disorder Patient Edition, Ver-
sion 2.0 (First et al., 1998). Prior to enrollment, male participants consumed more
than 150 alcoholic drinks (one drink contains 13.6 g of ethanol) per month for at
least  8 years; females consumed more than 80 drinks per month for at least 6 years.
PSU individuals were diagnosed with both alcohol dependence and dependence on
at  least one psychostimulant, with or without nicotine dependence and cannabis use
disorder. All PSU met  DSM-IV dependence criteria for at least one illicit substance
and 10.5% met  criteria for cannabis use disorder. Specifically, 12 PSU met  criteria
for  cocaine dependence (63%) and 2 of these were either abusing or dependent on
cannabis; 2 other PSU met criteria for both cocaine and methamphetamine depend-
ence (10.5%); and yet 2 others were dependent on both cocaine and opiates (10.5%);
2  other PSU met  criteria for methamphetamine dependence only (10.5%) and 1 for
opiate dependence only (5.5%). In the PSU group, 32% were non-smokers, includ-
ing  2 ex-smokers. All ALC participants met DSM-IV criteria for alcohol dependence
with or without nicotine dependence. 15 ALC participants (37%) were non-smokers,
including 6 ex-smokers; the proportion of smokers did not differ among ALC and
PSU. All ex-smokers among ALC and PSU individuals had stopped smoking for at least
5  years before the study. Within the ALC group, 2 individuals were currently abusing
cannabis, while 3 had past cannabis abuse, currently in full remission. In addition,
one ALC participant each showed past dependence on cocaine, amphetamines, or
opioids, but all were currently in full remission. Thus, while the ALC participants
were “clean” alcohol dependent individuals, the PSU participants were all depend-
ent on alcohol and 84% on cocaine; only about 11% in both groups had a current
or  past cannabis use disorder diagnosis. Other non-substance-related inclusion and
exclusion criteria were described previously (Durazzo et al., 2004). All ALC and PSU
participants were tested daily with breathalyzers for alcohol consumption and ran-
domly for substance use during outpatient treatment to ensure sobriety during the
one-month-abstinence period. Twenty-seven non-substance-using LD, without his-
tories of medical or psychiatric conditions known or suspected to influence brain
structural outcome measures were recruited from the local community. Twenty-one
of  the LD individuals (77%) were never-smokers, and the proportion of non-smokers
in the LD group was not significantly different from that in ALC or PSU (p ≥ 0.07) (see
Table 1).
2.2. Clinical assessment
Within one day of the MR study, participants completed standardized question-
naires for alcohol withdrawal (CIWA-Ar; Addiction Research Foundation Clinical
Institute of Withdrawal Assessment for Alcohol; Sullivan et al., 1989), depression
(Beck Depression Inventory; Beck, 1978) and anxiety symptomatology (State-Trait
Anxiety Inventory, Y-2, STAI; Spielberger et al., 1977). Alcohol consumption over
lifetime was assessed with the lifetime drinking history (LDH; Skinner and Sheu,
1982; Sobell and Sobell, 1990; Sobell et al., 1988). From the LDH, age of onset of
heavy drinking [defined as consuming >100 alcoholic drinks per month (male) or
>80 drinks per month (female)] was derived and the average number of alcoholic
drinks consumed per month over 1 year, 8 years before enrollment and over life-
time estimated. For PSU, substance use history (other than alcohol) was assessed
with an in-house questionnaire based on the Addiction Severity Index (McLellan
et al., 1992), NIDA Addictive Drug Survey (Smith, 1991), drinking history, and Axis I
disorders Patient Edition, Version 2.0 (SCID-I/P; First et al., 1998). The questionnaire
probed for information on phases of drug use for each substance that a participant
had  a current or past disorder diagnosis on. The variables recorded included age
of  first and last use, number of total lifetime phases, duration of individual and
total  lifetime phases (including phases of abstinence), frequency and quantity of
use  during each phase, and route of administration. Another variable recorded was
money spent per day on a substance, which was then converted to one metric, using
catchment area-specific conversion norms. Thus, monthly averages for grams of the
substances over 1 year prior to enrolment and over lifetime were estimated.
To evaluate the nutritional status and alcohol-related or other hepatocellular
injury, laboratory tests for serum, pre-albumin, alanine aminotransferase, aspar-
tate aminotransferase, and gamma-glutamyltransferase were obtained within three
days of each MR scan. The values of these variables in the liver and the white
blood cell counts were not significantly different between the groups. Table 1 shows
demographics, alcohol consumption and select blood variables for LD,  ALC and PSU.
2.3. Assessment of neurocognitive function
The neurocognitive domains and constituent measures evaluated were as fol-
lows (for details, see Durazzo et al., 2010): Executive skills: Short Categories Test,
color-word portion of the Stroop Test, Trail Making Test part B, Wechsler Adult
Intelligence Scale 3rd Edition (WAIS-III) Similarities, Wisconsin Card Sorting Test-
64:  Computer Version 2-Research Edition non-perseverative errors, perseverative
errors, and perseverative responses. Fine Motor Skills: Grooved Pegboard Test. Gen-
eral Intelligence: Ward-7 Full Scale IQ; based on WAIS-III Arithmetic, Block Design,
Digit Span, Digit Symbol, Information, Picture Completion, and Similarities sub-
tests. Learning and memory: Auditory-verbal: California Verbal Learning Test-II
Immediate Recall trials 1–5 (learning), Short and Long Delay Free Recall (memory).
Visuospatial: Brief Visuospatial Memory Test-Revised, Total Recall (learning) and
Delayed Recall (memory). Processing speed: WAIS-III Digit Symbol, Stroop Color
&  Word, WAIS-III Symbol Search Trail Making Test-A. Visuospatial skills: WAIS-
III  Block Design; Luria-Nebraska Item 99. Working memory: WAIS-III Arithmetic,
WAIS-III Digit Span. The raw scores for all neurocognitive measures (except Luria-
Nebraska Item 99 ratio) were converted to age-adjusted (e.g., Short Categories Test,
Stroop Color-Word Test, WAIS-III subtests) or age-and-education-adjusted (e.g.,
Trails A and B via Heaton Compendium Norms; Heaton et al., 1991) standardized
scores. The standardized scores were then converted to z-scores for all measures.
For the Luria-Nebraska Item 99 ratio, raw scores were converted to z-scores based
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Table 1
Demographics, substance use and blood variables for LD, ALC, and PSU (mean ± standard deviation).
Variable LD ALC PSU Pair-wise comparisons
N (females) 27 (3) 40 (3) 19 (0) –
Age  (years) 48.0 ± 8.0 50.2 ± 5.4 46.7 ± 7.1 LD = ALC = PSU (NS)
Education (years) 15.4 ± 2.2 13.5 ± 1.7 12.4 ± 1.1 LD > ALC (p < 0.001)
LD > PSU (p < 0.001)
ALC = PSU (NS)
Body  mass index (kg/m2) 26.5 ± 0.9 26.3 ± 0.7 28.3 ± 1.2 LD = ALC = PSU (NS)
AMNART 118.0 ± 6.9 114.4 ± 9.0 105.9 ± 8.3 LD > ALC (p < 0.001)
LD > PSU (p < 0.001)
ALC > PSU (p = 0.018)
1-yr  average drinks (month) 19 ± 21 402 ± 224 286 ± 273 ALC = PSU (NS)
LD < ALC (p < 0.001)
LD < PSU (p < 0.001)
8-yr  average drinks (month) 19 ± 18 325 ± 166 258 ± 231 ALC = PSU (NS)
LD < ALC (p < 0.001)
LD < PSU (p < 0.001)
Lifetime average drinks per month 19 ± 15 233 ± 120 246 ± 241 ALC = PSU (NS)
LD < ALC (p < 0.001)
LD < PSU (p < 0.001)
Age  of onset of heavy drinking – 23 ± 7 20 ± 5 ALC = PSU (NS)
Months of heavy drinking – 240 ± 97 239 ± 114 ALC = PSU (NS)
Duration of abstinence (days) – 32 ± 8 28 ± 11 ALC = PSU (NS)
Smokers, n (%) 6 (22) 25 (63) 13 (68) ALC = PSU (NS)
LD < ALC (2 = 0.07)
LD < PSU (2 = 0.09)
Medical comorbidities, n (%) – 18 (45) 11 (58) ALC = PSU (NS)
Psychiatric comorbidities, n (%) – 17 (43) 12 (63) ALC = PSU (NS)
Pre-albumin (g/dL) 29.7 ± 6.3 25.1 ± 6.4 30.8 ± 7.4 LD > ALC (p = 0.027)
ALC < PSU (p = 0.009)
LD = PSU (NS)
White blood cell counts (K/cm) 7.0 ± 1.7 7.7 ± 2.3 5.5 ± 1.2 LD < PSU (p = 0.022)
ALC < PSU (p = 0.001)
LD = ALC (NS)
Hematocrit (%) 43.8 ± 3.0 41.6 ± 4.1 43.2 ± 3.0 LD > ALC (p = 0.038)
LD = PSU (NS)
ALC = PSU (NS)
Beck  depression inventory 4.6 ± 4.3 10.9 ± 7.8 11.7 ± 8.5 LD < ALC (p < 0.001)
LD < PSU (p < 0.001)
ALC = PSU (NS)
State-trait anxiety inventory – state 33.0 ± 7.5 44.0 ± 11.1 42.8 ± 11.4 LD < ALC (p < 0.001)
LD < PSU (p < 0.001)
ALC = PSU (NS)
CIWA  1.4 ± 2.2 2.0 ± 2.8 1.9 ± 2.9 LD = ALC = PSU (NS)
1-yr average: number of alcoholic drinks per month over 1 year prior to study; 8 yr average: number of alcoholic drinks per month over 8 years prior to study; months heavy
drinking: number of months of greater than 100 alcoholic drinks per month; lifetime average: number of alcoholic drinks per month over lifetime; AMNART: American
National Adult Reading Test; CIWA: clinical institute of withdrawal assessment; NS: groups are not significantly different on the measure.
on the performance of 27 non-smoking light drinking controls (Durazzo et al., 2012),
since there are no published procedures available for this measure.
2.4. MRI  data acquisitions and processing
Whole brain three-dimensional T1-weighted coronal images and two-
dimensional T2-weighted oblique-axial images were acquired on a 1.5 Tesla
magnet (Vision, Siemens Medical Systems, Iselin, NJ), using Magnetization Pre-
pared Rapid Acquisition Gradient Echo imaging sequence (TR/TI/TE = 9/300/4 ms,
1  mm × 1 mm in-plane resolution, 1.5 mm  slabs) and spin-echo imaging sequence
(TR/TE2 = 2500/80 ms,  1 mm × 1 mm in-plane resolution, 3 mm slice thickness),
respectively.
After re-alignment of each subject’s T1- and T2-weighted images, the expecta-
tion  maximization segmentation method (Van Leemput et al., 1999) was  applied
to  the T1-weighted images to segment the brain into WM,  GM,  and CSF after co-
registration and correction for bias field intensity variation of the T1-weighted
images. The major lobes and subcortical regions were then parcellated by overlaying
the  tissue maps on a reference atlas containing landmarks of 36 brain regions (see
Studholme et al., 2001), including the regions reported here. The volumes of total
cortical GM and total lobar WM were calculated by summing the respective GM and
WM  values from the major lobes. The intracranial volume (ICV) was estimated by
summing all regional tissue and CSF volumes.
2.5. Statistics
Multivariate analysis of variance (MANOVA) assessed group differences on
age and education, differences between ALC and PSU on drinking and smoking
severities, days of abstinence, anxiety and depression symptoms, as well as basic
clinical laboratory measures (see Table 1). Multivariate analyses of covariance
(MANCOVAs) examined group differences on ICV-normalized volumes of 4 GM
regions (i.e., fGM, pGM, oGM, tGM), 4 WM regions (fWM,  pWM,  oWM, tWM),  5
subcortical regions (i.e., lenticular GM,  caudate GM,  thalamus GM,  total brainstem
and total cerebellum) and 5 CSF regions (i.e., fCSF, pCSF, oCSF, tCSF and ventricu-
lar  CSF) separately (f, p, o and t stand for frontal, parietal, occipital and temporal,
respectively). For total and regional cortical GM volumes and CSF, only age was
a  significant predictor of group variances and was therefore used as a covari-
ate.  For total and regional lobar WM volumes, only the body mass index (BMI)
contributed significantly to the variances and therefore was the only used covari-
ate.  Neither age nor BMI  was  a significant predictor of subcortical tissue volume
variance. Participants’ cigarette smoking status was  not a significant predictor of
any tissue volume; however, this exploration has to be treated with caution, as
the  proportion of smokers in the LD sample tended to be smaller than in the
patient groups. Given our a priori hypotheses, all MANCOVAs of tissue volumes
were followed-up with post hoc analyses (to assess group differences for GM,  WM,
or  CSF volumes) as well as pairwise and univariate t-tests (comparing LD, ALC
and  PSU). Also because of our a priori hypothesis, we did not correct for multi-
ple  comparisons. The reported p-values for GM are 1-tail, but those for WM and
CSF volumes are 2-tail, because PSU unexpectedly had greater WM and smaller
CSF volumes than LD and ALC. Although ALC and PSU did not differ significantly
on the frequency of medical and psychiatric co-morbidities, these comorbidities
were controlled for in all group comparisons. Effect sizes for pairwise comparisons
were calculated using Cohen’s d (Cohen, 1988). Associations of the MRI  out-
come measures with measures of neurocognitive test performance used Pearson’s
correlations.
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3. Results
3.1. Participant characterization
As shown in Table 1, LD, ALC, and PSU groups were not sig-
nificantly different on age and BMI, but LD had significantly more
years of education than ALC and PSU. ALC participants had signifi-
cantly lower pre-albumin levels than LD and PSU, whereas PSU had
significantly lower white blood cell counts than LD and ALC; how-
ever, pre-albumin levels and white blood cell counts in all groups
were within the normal range. Covarying for these variables did not
change the results of our main analyses. No other clinical laboratory
measures differed significantly among groups.
Regarding medical comorbidities, 9 ALC and 2 PSU tested posi-
tive for hepatitis C and 8 ALC and 4 PSU had medically controlled
hypertension. Inclusion/exclusion of individuals with these com-
mon  medical comorbidities from the statistical analyses did not
substantially change the results.
3.2. MRI  outcome measures
Table 2 shows ICV, ICV-normalized GM,  WM,  and subcortical
tissue volumes for all examined regions, and Table 3 shows the
ventricular and lobar ICV-normalized CSF volumes for all groups,
with effect sizes and p-values for group comparisons. All groups
were statistically similar on ICV.
3.2.1. ICV-normalized GM volumes. MANCOVA with age as covari-
ate revealed a significant main effect of age [F(2, 80) = 4.74,
p = 0.002] and group [F(2, 80) = 2.1, p = 0.041] for GM volumes.
Significant group effects were observed for total cortical GM
[F(2, 82) = 6.4, p = 0.003), fGM [F(2, 82) = 5.22, p = 0.008], pGM [F(2,
82) = 3.98, p = 0.023], and a trend for tGM [F(2, 82) = 2.80, p = 0.067].
Pairwise comparisons showed that ALC compared to LD had less
total cortical GM and smaller volumes of all but the occipital lobe.
PSU had less GM than LD in the temporal lobe only, and PSU had
larger frontal GM volume than ALC.
3.2.2. ICV-normalized WM volumes. MANCOVA with BMI  as covari-
ate revealed a significant main effect of BMI  [F(2, 80) = 3.1, p = 0.020]
and group [F(2, 80) = 3.58, p = 0.001] for WM volumes. Significant
group effects were observed for total WM and all lobar WM vol-
umes except oWM:  total WM [F(2, 82) = 9.93, p < 0.001], fWM  [F(2,
82) = 7.38, p = 0.001], pWM  [F(2, 82) = 9.99, p < 0.001], and tWM  [F(2,
82) = 6.19, p = 0.003]. Pairwise comparisons showed PSU with sig-
nificantly larger WM volumes than ALC for all four lobes and with
significantly larger fWM  and pWM  than LD. ALC showed WM vol-
umes similar to LD in all lobes except the temporal lobe, where
ALC had less WM than LD. Of all lobar WM volumes, pWM  volume
in PSU correlated positively with average amount of cocaine used
over the year prior to the study (r = 0.55, p = 0.044, uncorrected).
3.2.3. ICV-normalized subcortical volumes. MANOVA revealed a sig-
nificant main effect of group for subcortical tissues [F(2, 80) = 2.65,
p = 0.005]. Significant group effects were observed for thala-
mic  GM [F(2, 80) = 5.95, p = 0.004] and total cerebellar volume
[F(2, 80) = 3.25, p = 0.044]. Pairwise comparisons showed PSU had
smaller lenticular and thalamic GM volumes than LD, and ALC had
smaller thalamic GM and total cerebellar volumes than LD. ALC and
PSU had statistically similar volumes of all the subcortical regions
examined.
3.2.4. ICV-normalized CSF volumes. MANCOVA using age as covari-
ate revealed a significant main effect of age [F(2, 79) = 2.6, p = 0.043]
and group [F(2, 79) = 6.95, p < 0.001] for CSF volumes. Significant
group effects were observed for total sulcal CSF [F(2, 79) = 7.33,
p = 0.001], fCSF [F(2, 79) = 10.90, p < 0.001) and tCSF [F(2, 79) = 18.52,
p < 0.001]. Pairwise comparisons showed that ALC had more total
sulcal CSF in these regions than both LD and PSU (see Table 3). PSU
had similar sulcal CSF volumes than LD, except for the temporal
lobe, where PSU had less CSF than LD. Ventricular CSF volumes were
comparable among all three groups. Lobar CSF volumes did not
correlate significantly with the corresponding lobar WM volumes.
When the larger sample of 117 ALC was analyzed, the results
were consistent with those reported here in the smaller ALC sam-
ple: effect sizes were essentially the same while the significant
p-values reported here became even smaller. Thus, our findings in
the smaller ALC sample were representative of the larger sample
and not obtained by chance. Furthermore, excluding the six females
in the ALC and LD groups from analyses did not significantly change
the group means or any of the statistical analyses (e.g., tGM in LD
changed from 101.7 ± 4.7 with inclusion of women to 101.8 ± 4.9
without women, while the tGM means for ALC changed from
98.2 ± 5.0 with to 98.5 ± 4.8 without women; the corresponding
p-values of the t-tests changed from 0.008 to 0.011, respectively).
3.3. Correlations of MRI outcome measures with neurocognitive
domains
Correlations were obtained between ICV-normalized regional
tissue volumes that were not age-corrected and age-corrected neu-
rocognitive measures. In PSU, smaller pGM volume, although not
significantly different from ALC and LD, related to worse visuospa-
tial learning and memory (both r ≥ 0.50, p < 0.05); no lobar WM
volume in PSU correlated significantly with any of the neurocogni-
tive measures. In ALC, worse visuospatial learning correlated with
less total cortical GM and worse visuospatial skills with smaller fGM
volume (both r = 0.39, p ≤ 0.014); lower fine motor skills related to
smaller oGM volume (r = 0.43, p = 0.008). Also in ALC, lobar WM
volume did not correlate significantly with neurocognitive meas-
ures, except intelligence, which correlated negatively with oWM
(r = −0.36, p = 0.022). Finally, in the smaller group of LD, several cor-
relations between neurocognitive measures and mostly occipital
lobe volumes were observed, but these were all in the unexpected
direction.
4. Discussion
In this cross-sectional volumetric MRI  study, one-month-
abstinent alcohol dependent individuals without current psy-
chostimulant dependence (ALC), ALC individuals with current
dependence on at least one psychostimulant (PSU),and drug-free
LD differed significantly on regional GM and WM volumes normal-
ized to ICV: PSU had significantly larger lobar WM volumes than
LD and ALC, whereas ALC showed no regional WM volume differ-
ences compared to LD. GM volumes in PSU were lower only in the
temporal lobe, thalami and lenticular nuclei compared to LD. In
ALC however, most lobar cortical GM volumes, thalamic GM,  and
total cerebellar volume were significantly smaller than in LD. Con-
sistent with these tissue volume differences, sulcal CSF volumes of
the frontal and temporal lobes in PSU were smaller than in both ALC
and LD. All effect sizes for the significant WM differences between
PSU and LD or ALC were greater than 0.50, indicating moderate-
to-large magnitude group differences. Parietal WM volume in PSU
correlated positively with prior year cocaine use, suggesting a
substance-related parietal WM volume expansion. Frontal, parietal,
and total cortical GM volumes were associated with some critical
neurocognitive domain measures in both PSU and ALC, but not in
LD. These neuroimaging abnormalities may serve as polysubstance
abuse biomarkers and as potential targets for pharmacological and
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Table 2
ICV-normalized GM,  WM,  and subcortical volumes (1000×)  (mean ± standard deviation) for LD, ALC and PSU, together with effect sizes and p-values of pairwise follow-up
t-tests.
Region Group Volume Contrast Effect size p value
ICV (in mL) LD 1478.9 ± 125.9 LD = ALC 0.07 NS
ALC  1488.0 ± 125.8 LD = PSU 0.06 NS
PSU  1486.4 ± 139.3 ALC = PSU 0.01 NS
Total  GM LD 371.4 ± 13.3 LD > ALC 0.93 <0.001
ALC  357.8 ± 15.7 LD = PSU 0.44 NS
PSU  365.2 ± 14.7 ALC = PSU 0.47 NS
Frontal LD 148.5 ± 6.6 LD > ALC 0.65 0.003
ALC  143.6 ± 8.4 LD = PSU 0.24 NS
PSU  147.0 ± 5.9 ALC < PSU 0.47 0.038
Parietal LD 82.7 ± 4.6 LD > ALC 0.67 0.006
ALC  79.4 ± 5.3 LD = PSU 0.41 NS
PSU  80.8 ± 4.6 ALC = PSU 0.28 NS
Occipital LD 38.4 ± 3.6 LD = ALC 0.22 NS
ALC  36.6 ± 3.7 LD = PSU 0.03 NS
PSU  37.2 ± 3.1 ALC = PSU 0.18 NS
Temporal LD 101.4 ± 4.7 LD > ALC 0.58 0.042
ALC  98.6 ± 5.0 LD > PSU 0.50 0.045
PSU  98.3 ± 7.5 ALC = PSU 0.05 NS
Total  WM LD 267.3 ± 18.2 LD = ALC 0.33 NS
ALC  262.3 ± 11.6 LD < PSU 0.89 0.003
PSU  282.3 ± 15.2 ALC < PSU 1.48 <0.001
Frontal LD 140.2 ± 11.2 LD = ALC 0.18 NS
ALC  138.5 ± 7.6 LD < PSU 0.86 0.004
PSU  148.7 ± 8.3 ALC < PSU 1.28 <0.001
Parietal LD 64.4 ± 4.4 LD = ALC 0.29 NS
ALC  63.2 ± 3.6 LD < PSU 0.97 0.002
PSU  68.9 ± 4.9 ALC < PSU 1.33 <0.001
Occipital LD 23.5 ± 2.5 LD = ALC 0.22 NS
ALC  23.0 ± 2.0 LD < PSU 0.37 NS
PSU  24.5 ± 2.9 ALC < PSU 0.60 0.047
Temporal LD 39.2 ± 2.8 LD > ALC 0.65 0.013
ALC  37.5 ± 2.4 LD < PSU 0.37 NS
PSU  40.2 ± 2.6 ALC < PSU 1.08 0.002
Lenticular GM LD 4.8 ± 0.6 LD = ALC 0.42 NS
ALC  4.5 ± 0.8 LD > PSU 0.57 0.038
PSU  4.4 ± 0.8 ALC = PSU 0.12 NS
Caudate GM LD 4.8 ± 0.4 LD = ALC 0.00 NS
ALC  4.8 ± 0.5 LD = PSU 0.25 NS
PSU  4.9 ± 0.4 ALC = PSU 0.22 NS
Thalamic GM LD 4.6 ± 1.0 LD > ALC 0.77 0.002
ALC  3.9 ± 0.8 LD > PSU 0.81 0.005
PSU  3.9 ± 0.7 ALC = PSU 0.00 NS
Total  brainstem LD 18.6 ± 1.4 LD = ALC 0.00 NS
ALC  18.6 ± 1.3 LD = PSU 0.40 NS
PSU  19.2 ± 1.6 ALC = PSU 0.41 NS
Total  cerebellum LD 84.3 ± 6.6 LD > ALC 0.80 0.023
ALC  78.7 ± 7.3 LD = PSU 0.09 NS
PSU  83.7 ± 6.7 ALC = PSU 0.71 NS
Note: ICV-normalized tissue volume is defined here as [tissue volume/ICV] × 1000. Volumes are estimated means from a group model comparing all three groups. Reported
p-values are 1-tailed for GM and 2-tailed for all other volumes.
behavioral PSU-specific treatment aimed at decreasing the high
relapse rates in PSU.
MR-based structural neuroimaging of individuals with differ-
ent substance use disorders have yielded mixed findings regarding
brain tissue volume alterations. Smaller WM volumes (or density),
particularly of the frontal, temporal and cerebellar regions rela-
tive to drug-free controls were reported in middle-aged active and
abstinent users of cocaine and cannabis (Lim et al., 2008; Matochik
et al., 2005; Sim et al., 2007; Solowij et al., 2011). A few reports
showed similar WM volumes (or density) in active or abstinent
users of these substances compared to controls (Franklin et al.,
2002; Hanlon et al., 2011; Liu et al., 1998). However, enlarged vol-
umes or density of frontal, temporal, and subcortical WM were
reported in active amphetamine users (Bartzokis et al., 2000;
Thompson et al., 2004) and in amphetamine users in both early
and long-term abstinence (Jernigan et al., 2005; Tobias et al.,
2010). Here, we  found larger WM volumes in one-month absti-
nent PSU compared to both LD and one-month abstinent ALC.
Our PSU cohort was  dependent on alcohol (100%), cocaine (84%),
and methamphetamine (21%). When the four PSU individuals with
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Table  3
ICV-normalized ventricular and lobar CSF volumes (1000×) (mean ± standard deviation) for LD, ALC and PSU, together with effect sizes and p-values of follow-up t-tests.
Region Group Volume Contrast Effect size p value
Ventricular CSF LD 16.6 ± 5.2 LD = ALC 0.26 NS
ALC  18.1 ± 6.2 LD = PSU 0.04 NS
PSU  16.3 ± 8.5 ALC = PSU 0.24 NS
Total  sulcal CSF LD 190.5 ± 23.5 LD < ALC 0.84 0.001
ALC  208.7 ± 20.0 LD = PSU 0.03 NS
PSU  189.9 ± 15.5 ALC > PSU 1.05 0.003
Frontal LD  99.8 ± 11.6 LD < ALC 1.04 <0.001
ALC  112.5 ± 12.7 LD = PSU 0.01 NS
PSU 99.7 ± 9.5 ALC > PSU 1.14, <0.001
Parietal LD  47.7 ± 8.8 LD = ALC 0.23 NS
ALC  49.6 ± 7.6 LD = PSU 0.05 NS
PSU  51.6 ± 8.1 ALC = PSU 0.13 NS
Occipital LD  9.2 ± 2.1 LD = ALC 0.05 NS
ALC  9.0 ± 1.8 LD = PSU 0.36 NS
PSU  10.0 ± 2.3 ALC = PSU 0.14 NS
Temporal LD  33.8 ± 5.5 LD < ALC 0.66 0.007
ALC  37.2 ± 4.8 LD > PSU 1.22 0.001
PSU 28.5 ± 2.7 ALC > PSU 2.23 <0.001
Note: ICV-normalized CSF volume is defined here as [CSF volume/ICV] × 1000. Volumes are estimated means from a group model comparing all three groups. Reported
p-values are 2-tailed.
methamphetamine dependence were removed from the entire PSU
sample, all WM volumes remained significantly larger compared
to LD or ALC. This observation, together with the positive correla-
tion of parietal WM volume with cocaine use quantities in the PSU
suggests that, the larger WM volumes in our PSU cohort were not
driven simply by methamphetamine dependence in the PSU group.
Larger WM volumes in recently abstinent methamphetamine
users were postulated to be a result of tissue inflammation and/or
reactive astrogliosis as a response to tissue injury sustained from
the chronic substance abuse (Chang et al., 2007; Thompson et al.,
2004). A dose-related enhancement of neurological and histologi-
cal signs of acute encephalomyelitis (brain inflammation) following
in vivo administration of amphetamine or cocaine in rats was
described (Nunez et al., 2007). Also, in rats administered with
cocaine daily for 7 days, increases in glial fibrillary acidic protein
and vimentin expressions, the hallmarks of reactive astrocytes and
reactive gliosis (Pekny and Nilsson, 2005), were observed in the pre-
frontal cortex and nucleus accumbens at 3 weeks after substance
administration (Bowers and Kalivas, 2003). These findings support
the theory of brain tissue enlargement due to reactive astroglio-
sis. Therefore, it is not out of context to interpret the observed
larger lobar WM volumes in our PSU cohort as inflammation and/or
glial scarring associated with reactive astrogliosis observed at one
month after withdrawal from chronic consumption of both alcohol
and illicit substances.
Results of quantitative MRI-based regional GM volume/density
in individuals, who purportedly depended on or abused primarily
a single drug, have been inconsistent. Some cross-sectional studies
reported smaller regional GM volumes/densities (predominantly in
the frontal and temporal lobes, but also in thalamus) in both active
and abstinent users of cocaine (Fein et al., 2002; Franklin et al.,
2002; Lim et al., 2008; Sim et al., 2007), cannabis (Matochik et al.,
2005; Yucel et al., 2008), methamphetamine (Berman et al., 2008;
Thompson et al., 2004) and heroin (Yucel et al., 2008) compared to
controls. Others reported larger GM volumes/densities in cocaine
dependent individuals (Hanlon et al., 2011), cannabis abusers
(Cousijn et al., 2012) and methamphetamine abusers (Jernigan
et al., 2005) compared to controls; and yet others found no effects
of chronic cannabis misuse on brain morphology (Block et al.,
2000; Medina et al., 2009; Tzilos et al., 2005). On the other hand,
while previous reports on the effects of PSUD on brain GM vol-
umes are sparse, they are at least consistent: GM volumes were
reduced compared to age-matched drug-free controls in prefrontal
and temporo-parietal cortices of active cocaine dependent individ-
uals, many of whom were dependent also on other drugs (Ersche
et al., 2011, 2012), in the orbitofrontal cortex of polysubstance
abusers abstinent for at least 15 days (Liu et al., 1998), and in
prefrontal cortex of polysubstance dependent individuals absti-
nent for more than 2 years (Tanabe et al., 2009). This suggests
GM atrophy in active, short-term and long-term abstinent poly-
substance users. We found appreciable GM volume loss in our
one-month-abstinent PSU only in the temporal cortex, lenticu-
lar and thalamic GM.  The apparent “normal” frontal and parietal
cortical GM volume in our PSU sample could be the result of reac-
tive astrogliosis described above (where actual cortical GM loss
in the PSU may  be masked by a comparable amount of volume
gain from inflamed astrocytes), or where GM loss is offset by a
neuroadaptive response to the need for greater cognitive control
over substance use (e.g., Koehler et al., 2013). The discrepancies
between regional GM volume findings from our PSU participants
and those of the previous studies could relate to the differences
in age (our participants were on average 12–15 years older), the
duration and type of drugs used, and/or the duration of abstinence:
i.e., the younger cohorts in the previous studies could have been
less prone to brain inflammation from chronic substance use, brain
inflammation may  not be present in active users (as in Ersche et al.,
2011) or in polysubstance abusers abstinent for a few weeks (as
in Liu et al., 1998), or brain inflammation could have subsided
after 2 years of abstinence (as in Tanabe et al., 2009). However,
this is speculative and can only be tested in longitudinal studies
of abstinent polysubstance users: if our speculation/interpretation
were correct, the observed GM differences – and particularly the
larger WM volumes – should diminish with duration of absti-
nence as the substance withdrawal-related inflammation subsides
over time. Such a dynamic change has been suggested in absti-
nent methamphetamine users (Chang et al., 2007). Methodological
issues in studying brain effects of polysubstance dependence with
relevance to the above discussion were recently reviewed (Mackey
and Paulus, 2013).
Larger ventricular and lobar CSF volumes have been reported
consistently in short-term abstinent and active AUD individuals
compared to controls (Buhler and Mann, 2011). However, our find-
ings showed smaller CSF spaces in PSU compared to ALC with
similar drinking severities or controls, possibly compensating for
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the larger lobar WM volumes within the physical confines of the
skull.
Whereas both Ersche papers (Ersche et al., 2011, 2012) showed
larger subcortical GM volumes in currently using PSUD individ-
uals (caudate, lenticular nuclei, amygdala and cerebellum, some
of which may  be premorbid (Ersche et al., 2012)), our abstinent
PSU patients had smaller lenticular and thalamic GM as well as
normal caudate, cerebellar and brainstem volumes. As the authors
speculate that some of these increases may  reflect a compensatory
response to reduced dopamine neurotransmission, this may  have
normalized in our abstinent PSU sample.
Our study has limitations: the substance dependent cohort was
treatment-seeking and abstinent at time of study, and it included
only a few female participants. Our findings may  therefore not
generalize to female or treatment-naïve substance dependent indi-
viduals. The variance of the subcortical volume measures obtained
with our automated segmentation method (expectation maxi-
mization segmentation) is larger than that shown in manually
outlined structures of cocaine dependent individuals (Jacobsen
et al., 2001), which might have made it impossible to detect small
group differences. The measured tissue volumes comprise of sev-
eral sub-regions that subserve specific cognitive functions. Thus,
our lobar outcome measures lack functional specificity, which
likely contributed to the few correlations with neurocognitive
measures. Finally, we did not screen participants for DSM-IV Axis
II disorders, such as antisocial personality disorders (Fein et al.,
2007; Grant et al., 2004; Pridmore et al., 2005), nor did we mea-
sure potential group differences in nutrition, exercise and genetic
predispositions. All these conditions may  also influence brain mor-
phometry and should ideally be considered in future studies of both
treatment-naïve and treatment-seeking individuals with well-
defined dependence on alcohol and illicit substances. To address
the issue of regional specificity of volume changes within the rela-
tively large lobes and to increase the functional relevance of such
measures, reliable segmentation and examination of small brain
regions or of the cortical ribbon may  be needed, such as provided
by whole-brain voxel-based morphometry and cortical thickness
measures (see e.g., Cardenas et al., 2011; Durazzo et al., 2011;
Ersche et al., 2011).
These limitations notwithstanding, our neuroimaging study
reveals gross brain structural differences between PSU and ALC
that may  have implications for different treatment approaches
of polysubstance dependence and alcohol dependence. The find-
ings complement previous neuronal and glial differences we
detected in the frontal lobe of these substance dependent groups
(Abé et al., 2013). Here, we confirmed commonly reported
smaller lobar GM and cerebellar volumes and more sulcal CSF in
one-month-abstinent middle-aged ALC compared to age-matched
LD. However, these volume measures were largely unaffected in
one-month-abstinent alcohol dependent PSU. Furthermore, PSU
had larger lobar WM volumes than both ALC and LD. The larger
WM and the lack of apparent GM volume loss in PSU, despite
a very long drinking history similar to that of ALC who  showed
marked cortical GM volume loss, suggest hypertrophic processes
in short-term abstinent PSU, perhaps astrogliosis associated with
neuro-inflammation. These processes may  mask underlying corti-
cal GM tissue loss associated with chronic polysubstance misuse.
Role of funding source
This work was supported by the National Institutes of Health
AA10788 (DJM), DA025202 (DJM), NIDA DA24136 (TCD) and by the
use of resources and facilities at the San Francisco Veterans Admin-
istration Medical Center. Apart from funding, the funding bodies did
not contribute to this research and preparation of this manuscript.
Contributors
The authors are Anderson Mon, Timothy C. Durazzo, Christoph
Abe, Stefan Gazdzinski, David Pennington, Thomas Schmidt and
Dieter J. Meyerhoff. Drs. Anderson Mon, Stefan Gazdzinski and
Christoph Abe acquired and processed the MRI  data. Dr.  David
Pennington and Mr  Thomas Schmidt obtained and processed the
neurocognitive data. Drs. Anderson Mon, Timothy Durazzo, Stefan
Gazdzinski and Dieter Meyerhoff analyzed all data. Drs. Anderson
Mon  and Dieter Meyerhoff prepared the first drafts; and thereafter
all other authors contributed to the final manuscript submitted
here.
Conflict of interest
The authors have no disclosures or conflicts of interest related
to this research to report.
Acknowledgements
We  thank Mary Rebecca Young, Ricky Chen, and Drs. Ellen
Herbst and Peter Banys of the Veterans Administration Substance
Abuse Day Hospital, and Dr. David Pating, Karen Moise and their col-
leagues at the Kaiser Permanente Chemical Dependency Recovery
Program in San Francisco for their valuable assistance in recruiting
participants. We  also extend our gratitude to the study participants,
who made this research possible.
References
Abé, C., Mon, A., Durazzo, T.C., Pennington, D.L., Schmidt, T., Meyerhoff, D.J.,
2013. Polysubstance and alcohol dependence: unique differences in magnetic
resonance-derived brain metabolite concentrations. Drug Alcohol Depend. 130,
30–37.
Barros-Loscertales, A., Garavan, H., Bustamante, J.C., Ventura-Campos, N., Llopis, J.J.,
Belloch, V., Parcet, M.A., Avila, C., 2011. Reduced striatal volume in cocaine-
dependent patients. Neuroimage 56, 1021–1026.
Bartzokis, G., Beckson, M.,  Lu, P.H., Edwards, N., Rapoport, R., Wiseman, E., Bridge, P.,
2000. Age-related brain volume reductions in amphetamine and cocaine addicts
and  normal controls: implications for addiction research. Psychiatry Res. 98,
93–102.
Beck, A.T., 1978. Depression Inventory. Center for Cognitive Therapy, Philadelphia.
Berman, S., O’Neill, J., Fears, S., Bartzokis, G., London, E.D., 2008. Abuse of
amphetamines and structural abnormalities in the brain. Ann. N. Y. Acad. Sci.
1141, 195–220.
Block, R.I., Erwin, W.J., Ghoneim, M.M.,  2002. Chronic drug use and cognitive impair-
ments. Pharmacol. Biochem. Behav. 73, 491–504.
Block, R.I., O’Leary, D.S., Ehrhardt, J.C., Augustinack, J.C., Ghoneim, M.M.,  Arndt, S.,
Hall, J.A., 2000. Effects of frequent marijuana use on brain tissue volume and
composition. Neuroreport 11, 491–496.
Bowers, M.S., Kalivas, P.W., 2003. Forebrain astroglial plasticity is induced fol-
lowing withdrawal from repeated cocaine administration. Eur. J. Neurosci. 17,
1273–1278.
Buhler, M., Mann, K., 2011. Alcohol and the human brain: a systematic review of
different neuroimaging methods. Alcohol. Clin. Exp. Res. 35, 1771–1793.
Cardenas, V.A., Durazzo, T.C., Gazdzinski, S., Mon, A., Studholme, C., Meyerhoff,
D.J., 2011. Brain morphology at entry into treatment for alcohol dependence
is  related to relapse propensity. Biol. Psychiatry 70, 561–567.
Chang, L., Alicata, D., Ernst, T., Volkow, N., 2007. Structural and metabolic brain
changes in the striatum associated with methamphetamine abuse. Addiction
102 (Suppl. 1), 16–32.
Cohen, J., 1988. Statistical Power Analysis for the Behavioral Sciences. Lawrence
Erlbaum Associates, Hillsdale, NJ.
Cousijn, J., Wiers, R.W., Ridderinkhof, K.R., van den Brink, W.,  Veltman, D.J., Goudri-
aan, A.E., 2012. Grey matter alterations associated with cannabis use: results
of a VBM study in heavy cannabis users and healthy controls. Neuroimage 59,
3845–3851.
Durazzo, T.C., Fryer, S.L., Rothlind, J.C., Vertinsk, M.,  Gazdzinski, S., Mon, A., Meyer-
hoff, D.J., 2010. Measures of learning, memory and processing speed accurately
predict smoking status in short-term abstinent treatment-seeking alcohol-
dependent individuals. Alcohol 45, 507–513.
Durazzo, T.C., Gazdzinski, S., Banys, P., Meyerhoff, D.J., 2004. Cigarette smoking
exacerbates chronic alcohol-induced brain damage: a preliminary metabolite
imaging study. Alcohol. Clin. Exp. Res. 28, 1849–1860.
Durazzo, T.C., Meyerhoff, D.J., 2007. Neurobiological and neurocognitive effects of
chronic cigarette smoking and alcoholism. Front. Biosci. 12, 4079–4100.
A. Mon et al. / Drug and Alcohol Dependence 144 (2014) 170–177 177
Durazzo, T.C., Meyerhoff, D.J., Nixon, S.J., 2012. A comprehensive assessment of neu-
rocognition in middle-aged chronic cigarette smokers. Drug Alcohol Depend.
122, 105–111.
Durazzo, T.C., Mon, A., Gazdzinski, S., Yeh, P.-H., Meyerhoff, D.J., 2014.
Serial longitudinal MRI  data indicate non-linear regional gray matter vol-
ume  recovery in abstinent alcohol dependent individuals. Addict. Biol.,
http://dx.doi.org/10.1111/adb.12180.
Durazzo, T.C., Tosun, D., Buckley, S., Gazdzinski, S., Mon, A., Fryer, S.L., Meyerhoff, D.J.,
2011. Cortical thickness, surface area, and volume of the brain reward system in
alcohol dependence: relationships to relapse and extended abstinence. Alcohol.
Clin. Exp. Res. 35, 1187–1200.
Ersche, K.D., Barnes, A., Jones, P.S., Morein-Zamir, S., Robbin, T.W., Bullmore, E.T.,
2011. Abnormal structure of frontostriatal brain systems is associated with
aspects of impulsivity and compulsivity in cocaine dependence. Brain 134,
2013–2024.
Ersche, K.D., Jones, P.S., Williams, G.B., Turton, A.J., Robbins, T.W., Bullmore, E.T.,
2012. Abnormal brain structure implicated in stimulant drug addiction. Science
335, 601–604.
Fein, G., Di Sclafani, V., Finn, P., Scheiner, D.L., 2007. Sub-diagnostic psychiatric
comorbidity in alcoholics. Drug Alcohol Depend. 87, 139–145.
Fein, G., Di Sclafani, V., Meyerhoff, D.J., 2002. Prefrontal cortical volume reduction
associated with frontal cortex function deficit in 6-week abstinent crack-cocaine
dependent men. Drug Alcohol Depend. 68, 87–93.
First, M.B., Spitzer, R.L., Gibbon, M.,  Williams, J.B.W., 1998. Structured Clinical Inter-
view for DSM-IV Axis I Disorders – Patient Edition (SCID-I/P, Version 2.0, 8/98
Revision). Biometrics Research Department, New York, NY.
Franklin, T.R., Acton, P.D., Maldjian, J.A., Gray, J.D., Croft, J.R., Dackis, C.A., O’Brien,
C.P., Childress, A.R., 2002. Decreased gray matter concentration in the insular,
orbitofrontal, cingulate, and temporal cortices of cocaine patients. Biol. Psychi-
atry 51 (2), 134–142.
Gazdzinski, S., Durazzo, T.C., Meyerhoff, D.J., 2005a. Temporal dynamics and deter-
minants of whole brain tissue volume changes during recovery from alcohol
dependence. Drug Alcohol Depend. 78, 263–273.
Gazdzinski, S., Durazzo, T.C., Studholme, C., Song, E., Banys, P., Meyerhoff, D.J., 2005b.
Quantitative brain MRI  in alcohol dependence: preliminary evidence for effects
of  concurrent chronic cigarette smoking on regional brain volumes. Alcohol.
Clin. Exp. Res. 29, 1484–1495.
Grant, B., Stinson, F., Dawson, D.P.C., Dufour, M.,  Compton, W.,  Pickering, R.P., Kaplan,
K.,  2004. Prevalence and co-occurence of substance use disorders and indepen-
dent mood and anxiety disorders. Arch. Gen. Psychiatry 61, 807–816.
Hanlon, C.A., Dufault, D.L., Wesley, M.J., Porrino, L.J., 2011. Elevated gray and white
matter densities in cocaine abstainers compared to current users. Psychophar-
macology (Berl.) 218, 681–692.
Heaton, R.K., Grant, I., Matthews, C.G., 1991. Comprehensive Norms for an Expanded
Halstead-Reitan Battery Demographic Corrections, Research Findings and Clin-
ical Applications. Psychol. Assess. Res., Inc., Odessa, FL.
Jacobsen, L.K., Giedd, J.N., Gottschalk, C., Kosten, T.R., Krystal, J.H., 2001. Quantitative
morphology of the caudate and putamen in patients with cocaine dependence.
Am.  J. Psychol. 158, 486–489.
Jernigan, T.L., Gamst, A.C., Archibald, S.L., Fennema-Notestine, C., Mindt, M.R., Mar-
cotte, T.D., Heaton, R.K., Ellis, R.J., Grant, I., 2005. Effects of methamphetamine
dependence and HIV infection on cerebral morphology. Am. J. Psychiatry 162,
1461–1472.
Koehler, S., Hasselmann, E., Wüstenberg, T., Heinz, A., Romanczuk-Seiferth, N., 2013.
Higher volume of ventral striatum and right prefrontal cortex in pathological
gambling. Brain Struct. Funct., http://dx.doi.org/10.1007/s00429-013-0668-6
(epub ahead of print).
Lim, K.O., Wozniak, J.R., Muelle r, B.A., Franc, D.T., Specker, S.M., Rodriguez,
C.P., Silverman, A.B., Rotrosen, J.P., 2008. Brain macrostructural and micro-
structural abnormalities in cocaine dependence. Drug Alcohol Depend. 92,
164–172.
Liu, X., Matochik, J.A., Cadet, J.L., London, E.D., 1998. Smaller volume of prefrontal
lobe  in polysubstance abusers: a magnetic resonance imaging study. Neuropsy-
chopharmacology 18, 243–252.
Mackey, S., Paulus, M.,  2013. Are there volumetric brain differences associated with
theuse of cocaine and amphetamine-type stimulants? Neurosci. Biobehav. Rev.
37,  300–316.
Matochik, J.A., Eldreth, D.A., Cadet, J.L., Bolla, K.I., 2005. Altered brain tissue compo-
sition in heavy marijuana users. Drug Alcohol Depend. 77, 23–30.
McLellan, A.T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati,
H.,  Argeriou, M.,  1992. The fifth edition of the addiction severity index. J. Subst.
Abuse Treat. 9, 199–213.
Medina, K.L., McQueeny, T., Nagel, B.J., Hanson, K.L., Yang, T.T., Tapert, S.F., 2009.
Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle
gender effects. Addict. Biol. 14, 457–468.
Medina, K.L., Shear, P.K., Schafer, J., Armstrong, T.G., Dyer, P., 2004. Cognitive func-
tioning and length of abstinence in polysubstance dependent men. Arch. Clin.
Neuropsychol. 19, 245–258.
Nunez, M.J., Balboa, J., Rey-Mendez, M.,  Brenlla, J., Gonzalez-Peteiro, M.,  Rodrigo, E.,
Freire-Garabal, M.,  2007. Effects of amphetamine and cocaine on the develop-
ment of acute experimental allergic encephalomyelitis in Lewis rats. Hum. Exp.
Toxicol. 26, 637–643.
O’Neill, J., Cardenas, V.A., Meyerhoff, D.J., 2001. Separate and interactive effects
of  cocaine and alcohol dependence on brain structures and metabolites:
quantitative MRI  and proton MR spectroscopic imaging. Addict. Biol. 6,
347–361.
Oscar-Berman, M., 2000. NIAAA Research Monograph No. 34: Neuropsychological
Vulnerabilities in Chronic Alcoholism. In: Review of NIAAA’s Neuroscience and
Behavioral Research Portfolio. NIAAA, Bethesda, MD,  pp. 437–472.
Pekny, M.,  Nilsson, M.,  2005. Astrocyte activation and reactive gliosis. Glia 50,
427–434.
Pridmore, S., Chambers, A., McArthur, M.,  2005. Neuroimaging in psychopathy. Aust.
N.  Z. J. Psychol. 39, 856–865.
Pfefferbaum, A., Sullivan, E.V., Mathalon, D.H., Shear, P.K., Rosenbloom, M.J.,
Lim, K.O., 1995. Longitudinal changes in magnetic resonance imaging brain
volumes in abstinent and relapsed alcoholics. Alcohol Clin. Exp. Res. 19,
1177–1191.
Sim, M.E., Lyoo, I.K., Streeter, C.C., Covell, J., Sarid-Segal, O., Ciraulo, D.A., Kim, M.J.,
Kaufman, M.J., Yurgelun-Todd, D.A., Renshaw, P.F., 2007. Cerebellar gray matter
volume correlates with duration of cocaine use in cocaine-dependent subjects.
Neuropsychopharmacology 32, 2229–2237.
Skinner, H.A., Sheu, W.J., 1982. Reliability of alcohol use indices. The Lifetime Drink-
ing  History and the MAST. J. Stud. Alcohol 43, 1157–1170.
Smith, S.S., 1991. Addictive Drug Survey Manual. NIDA Addiction Research Center,
Baltimore, MD.
Sobell, L.C., Sobell, M.B., 1990. Self-reports issues in alcohol abuse: state of the art
and  future directions. Behav. Assess. 12, 77–90.
Sobell, L.C., Sobell, M.B., Riley, D.M., Schuller, R., Pavan, D.S., Cancilla, A., Klajner,
F., Leo, G.I., 1988. The reliability of alcohol abusers’ self-reports of drink-
ing  and life events that occurred in the distant past. J. Stud. Alcohol 49,
225–232.
Solowij, N., Yucel, M.,  Respondek, C., Whittle, S., Lindsay, E., Pantelis, C., Lubman,
D.I., 2011. Cerebellar white-matter changes in cannabis users with and without
schizophrenia. Psychol. Med. 41, 2349–2359.
Spielberger, C.D., Gorsuch, R.L., Lushene, R., Vagg, P.R., Jacobs, G.A., 1977. Self-
Evaluation Questionnaire. Consulting Psychology Press, Palo Alto.
Stavro, K., Pelletier, J., Potvin, S., 2012. Widespread and sustained cognitive deficits
in  alcoholism: a meta-analysis. Addict. Biol. 18, 203–213.
Studholme, C., Cardenas, V., Weiner, M.,  2001. Multi-Scale Image and Multi-Scale
Deformation of Brain Anatomy for Building Average Brain Atlases. Paper pre-
sented at the SPIE Medical Imaging Conference.
Sullivan, J., Sykora, K., Schneiderman, J., Naranjo, C., Sellers, E., 1989. Assessment
of  alcohol withdrawal: the revised clinical institute withdrawal assessment for
alcohol scale. Br. J. Addict. 84, 1353–1357.
Tanabe, J., Tregellas, J.R., Dalwani, M.,  Thompson, L., Owens, E., Crowley, T., Banich,
M.,  2009. Medial orbitofrontal cortex gray matter is reduced in abstinent
substance-dependent individuals. Biol. Psychiatry 65, 160–164.
Thompson, P.M., Hayashi, K.M., Simon, S.L., Geaga, J.A., Hong, M.S., Sui, Y., Lee, J.Y.,
Toga, A.W., Ling, W.,  London, E.D., 2004. Structural abnormalities in the brains
of  human subjects who use methamphetamine. J. Neurosci. 24, 6028–6036.
Tobias, M.C., O’Neill, J., Hudkins, M.,  Bartzokis, G., Dean, A.C., London, E.D., 2010.
White-matter abnormalities in brain during early abstinence from metham-
phetamine abuse. Psychopharmacology (Berl.) 209, 13–24.
Trabert, W.,  Betz, T., Niewald, M.,  Huber, G., 1995. Significant reversibility of alcoholic
brain shrinkage within 3 weeks of abstinence. Acta Psychiatr. Scand. 92, 87–90.
Tzilos, G.K., Cintron, C.B., Wood, J.B., Simpson, N.S., Young, A.D., Pope Jr., H.G.,
Yurgelun-Todd, D.A., 2005. Lack of hippocampal volume change in long-term
heavy cannabis users. Am.  J. Addict. 14, 64–72.
Van Eijk, J., Demirakca, T., Frischknecht, U., Hermann, D., Mann, K., Ende, G.,  2013.
Rapid partial regeneration of brain volume during the first 14 days of abstinence
from alcohol. Alcohol Clin. Exp. Res. 37, 67–74.
Van Leemput, K., Maes, F., Vandermeulen, D., Suetens, P., 1999. Automated model-
based tissue classification of MR images of the brain. IEEE Trans. Med. Imaging
18, 897–908.
Yucel, M.,  Solowij, N., Respondek, C., Whittle, S., Fornito, A., Pantelis, C., Lubman, D.I.,
2008. Regional brain abnormalities associated with long-term heavy cannabis
use. Arch. Gen. Psychol. 65, 694–701.
Zipursky, R.B., Lim, K.C., Pfefferbaum, A., 1989. MRI  study of brain changes with
short-term abstinence from alcohol. Alcohol Clin. Exp. Res. 13, 664–666.
